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Abstract
Deep brain stimulation (DBS) has been proposed for severe, chronic, treatment-refractory obsessive-compulsive disorder (OCD)
patients. Although serious adverse events can occur, only a few studies report on the safety proﬁle of DBS for psychiatric
disorders. In a prospective, open-label, interventional multi-center study, we examined the safety and efﬁcacy of electrical
stimulation in 30 patients with DBS electrodes bilaterally implanted in the anterior limb of the internal capsule. Safety, efﬁcacy,
and functionality assessments were performed at 3, 6, and 12 months post implant. An independent Clinical Events Committee
classiﬁed and coded all adverse events (AEs) according to EN ISO14155:2011. All patients experienced AEs (195 in total), with
the majority of these being mild (52% of all AEs) or moderate (37%). Median time to resolution was 22 days for all AEs and the
etiology with the highest AE incidence was ‘programming/stimulation’ (in 26 patients), followed by ‘New illness, injury,
condition’ (13 patients) and ‘pre-existing condition, worsening or exacerbation’ (11 patients). Sixteen patients reported a total of
36 serious AEs (eight of them in one single patient), mainly transient anxiety and affective symptoms worsening (20 SAEs).
Regarding efﬁcacy measures, Y-BOCS reduction was 42% at 12 months and the responder rate was 60%. Improvements in
GAF, CGI, and EuroQol-5D index scores were also observed. In sum, although some severe AEs occurred, most AEs were mild
or moderate, transient and related to programming/stimulation and tended to resolve by adjustment of stimulation. In a severely
treatment-resistant population, this open-label study supports that the potential beneﬁts outweigh the potential risks of DBS.
Introduction
Obsessive-compulsive disorder (OCD) is a chronic and
disabling neuropsychiatric disorder characterized by the
presence of obsessions—upsetting and repetitive thoughts,
images, or impulses, experienced as intrusive, that persist
despite efforts to suppress, resist, or ignore them, and/or
compulsions, repetitive, ritualized behaviors or mental acts
intended to neutralize the anxiety induced by the obsessions
[1]. OCD has a lifetime prevalence of 2.3% [2] and can
cause profound, life-impairing stress and substantial dys-
function in social, work, and family life [3]. According to
the World Health Organization, OCD is among the top 20
causes of illness-related disability for people aged 15–44
years [4]. Despite exhaustive use of optimal cognitive-
behavioral therapy and pharmacological treatment algo-
rithms, an estimated 10% of OCD patients remain unre-
sponsive to all therapies and suffer from severe symptoms
leading to marked functional impairment [5].
For this group of extremely disabled patients, deep brain
stimulation (DBS) has been recently approved as an alter-
native to stereotactic ablative neurosurgery. Medtronic
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Reclaim™ DBS Therapy for OCD received a humanitarian
device exemption from the FDA and received a CE mark
for its use in intractable severe OCD in 2009. ‘Approved’
thus refers to this regulatory approval rather than the sub-
sequently published consensus on guidelines from physi-
cian societies [6]. Although DBS is an invasive procedure
with potentially serious adverse events (SAEs), the techni-
que has several advantages: it is reversible, it allows for
optimization of parameters—selection of active electrode
contacts, frequency, polarity, and intensity—for individual
patients, provides opportunities to study the brain circuitry
involved, and enables sham treatment studies that may help
to obtain stronger evidence for surgical therapies.
Several DBS targets have been tested in OCD, including
structures around the ventral capsule/ventral striatum (VC/
VS), the subthalamic nucleus (STN) and the inferior thalamic
peduncle [7]. The approved indication prescribes stimulation
of the anterior limb of the internal capsule (AIC), which could
be achieved with an active electrode located in AIC itself, the
VC/VS interface, the neighboring nucleus accumbens or the
bed nucleus of the stria terminalis (BST) [8].
To date, seven studies that included randomized, con-
trolled assessments of DBS in 69 OCD patients have been
published. However, most of the literature on effectiveness of
DBS consists of uncontrolled case reports, series or trials [8–
14]. Recent systematic reviews and meta-analyses estimate
reduction in OCD severity in response to DBS to be 45–48%.
The global percentage of responders—patients with at least a
35% reduction in Yale-Brown Obsessive-Compulsive Scale
(Y-BOCS) scores—reaches 58–67% [7, 8, 15, 16].
Relatively little is known on the detailed safety proﬁle of
DBS for psychiatric disorders in general, and speciﬁcally
for OCD. A recent review suggests that adverse events
(AEs) of DBS in OCD, Gilles de La Tourette’s syndrome
and treatment-resistant depression are similar to those
reported for DBS use in movement disorders, with the
majority of complications being transient and related to
stimulation [17]. Nevertheless, long-term morbidity occur-
red in 16.5% of the cases and permanent neurological
complications due to intracerebral hemorrhage (ICH) were
reported in 2.2% of the patients [17]. To allow an adequate
assessment of the beneﬁt-risk ratio of DBS for OCD, further
studies with a rigorous report of positive as well as negative
outcomes and AEs are mandatory.
This study constitutes the ﬁrst prospective, open-label,
interventional multi-center study aimed to monitor the
safety and performance of electrical stimulation of the AIC
in patients with chronic, severe, treatment-resistant OCD
(ClinicalTrial.gov identiﬁer: NCT01135745). It was spon-
sored by Medtronic, as part of the postmark clinical follow-
up commitment made to the notiﬁed body that granted CE
mark for the therapy in Europe. The objectives of this study
were (1) to characterize AEs associated with the implant
procedure, the device and the bilateral stimulation of the
AIC in OCD patients and (2) to assess the efﬁcacy of DBS
treatment on OCD symptoms, quantiﬁed with the Y-BOCS,
from baseline to 3, 6, and 12 months after implantation.
Materials and methods
For detailed ‘Materials and methods”, refer to Supplemen-
tary Appendix.
Patients suffered from severe to extreme OCD according
to the Y-BOCS (total score of at least 30/40) [18], and were
seriously impaired in daily functioning. This level of
impairment had persisted for ≥5 years despite a minimum of
three adequate pharmacological trials with ﬁrst- and/or
second-line medications (at least one trial had to be with
clomipramine) and a supplementary augmentation trial (aty-
pical neuroleptics). Included patients had not responded to an
adequate trial of cognitive-behavioral therapy. Patients were
excluded if they had a current Axis I disorder that was pri-
mary to OCD according to the Structured Clinical Interview
for DSM-IV-TR Axis I Disorders (SCID-I) [19], if they met
criteria for substance abuse or dependence ≤6 months prior to
the screening test, if they made suicide attempts ≤3 months
prior to screening (or posed a serious suicide risk) or if they
had any neurological condition that could hinder the stimu-
lation procedure (more details on inclusion/exclusion criteria
are shown in Supplementary Table 1 and a diagram of
inclusion is shown in Supplementary Fig. 1).
After a preoperative MRI, model 3391 DBS leads
[Medtronic, Inc., Minneapolis, MN, USA] were stereo-
tactically implanted in the bilateral AIC and connected
subcutaneously to unilateral or bilateral dual-channel Model
7428 Kinetra™, bilateral single-channel Model 7426 Sole-
tra™ or unilateral dual-channel Model 37601 Activa™ PC
neurostimulators [Medtronic, Inc.]. Activa™ PC and the
single-channel Model 37602 and 37603 Activa™ SC neu-
rostimulators have since received CE mark for OCD.
Implanted 3391 electrodes feature 3-mm-long contacts 4
mm apart, spanning a total length of 24 mm. The objective
of electrode location was to enable stimulation of the AIC,
but did not impose a detailed targeting technique. Each
neurosurgeon chose surgical trajectory and lead end point,
based on clinical expertize and individual anatomical
characteristics of the patient. A commercialized image-
guided software system was used for all lead implantations.
Postoperative imaging (CT and/or MRI) was performed to
document lead location. Following surgical recovery,
patients underwent DBS parameter selection to identify
optimal parameter settings for the treatment phase (within
4 weeks of implantation). During this treatment phase,
safety and efﬁcacy assessments were performed at 3, 6, and
12 months post implant (study ﬂow is shown in
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Supplementary Fig. 2 and study timeline is shown in Sup-
plementary Fig. 3). Stimulation parameters and psycho-
tropic medication could be modiﬁed in response to AEs
and/or in order to improve efﬁcacy as necessary. All AEs
and SAEs had to be followed up in accordance with good
medical practice until resolved or judged no longer clini-
cally signiﬁcant. An independent Clinical Events Commit-
tee reviewed all AEs. The deﬁnition of AEs and SAEs is
provided in Supplementary Appendix.
To characterize DBS efﬁcacy, the following measure-
ments were taken: the Y-BOCS (for assessing the severity of
obsessive-compulsive symptoms), the Global Assessment of
Functioning (GAF) [20, 21] for measuring psychological,
social and occupational functioning, the Montgomery-
Åsberg Depression Rating Scale [22] for assessing the
severity of depressive symptoms, the Young Mania Rating
Scale (YMRS) [23] for measuring the severity of manic
symptoms, the Clinical Global Impressions Scale (CGI) [24]
for rating the severity of psychiatric illness and symptom
improvement, and the EuroQol group-5 Dimensional (EQ-
5D) as a measure of health outcome [25].
Results
Patients
Demographic data and OCD characteristics are summarized
in Supplementary Table 2. Thirty-one patients were enrol-
led and 30 patients implanted across eight centers in Europe
and Israel. One additional patient was included but asked to
retract his data after ﬁnishing the study and has not been
included in this report. Half the patients were male (15,
48%) and mean (standard deviation [SD]) age at enrollment
was 41.0 (9.9) years. The vast majority exhibited a high
impairment in social and occupational functioning, with
mean (SD) GAF score at baseline 39.0 (8.1). Mean baseline
Y-BOCS total score was 34.7 (2.9), indicating extreme
OCD. Current and lifetime prevalence of psychiatric
comorbidities were assessed through SCID-I. The most
common lifetime comorbidities were mood disorders (19
patients, 61%), anxiety disorders (other than OCD) (12,
39%) and substance use disorders (7, 23%), and the most
common current comorbidities were mood disorders (9,
29%), anxiety disorders (9, 29%) and somatoform disorders
(5, 16%). Almost half of the patients (15, 48%) did not
report any current psychiatric comorbidity at screening.
Implant procedure and therapy delivery
Several neurostimulators are CE marked for OCD, and the
neurostimulator model used in the majority of 30 implanted
patients was Kinetra™ (27, 90%). Of these patients, 19 (63%
of all implanted) had one neurostimulator and a further 8
(27%) had two neurostimulators implanted. Of the remaining
3 patients, 2 (7%) had Activa™ PC neurostimulators (one for
each patient) and 1 patient had two Soletra™ neuro-
stimulators. DBS stimulation was initiated in all 30 implanted
patients. At the Month 12 visit, 27 (90%) patients still had
active devices, although 1 was not receiving effective sti-
mulation due to low impedance. Of the 26 patients receiving
effective stimulation, 25 received bilateral stimulation as
intended per approved indication and 1 received unilateral
stimulation. Leads were programmed with 1 active contact,
except for 5 leads with 2 active contacts, and 1 lead with 3
active contacts, totaling 58 active contacts at Month 12. The
anatomical location of the geometric center of active contacts
at Month 12 is shown in Fig. 1.
At the last available visit that patients received stimula-
tion (including the 1 patient with low impedance at Month
12, and adding 1 patient with bilateral stimulation at an
earlier visit), 55 hemispheres were stimulated. Lead location
varied according to individual patient anatomy and the
neurosurgeon’s clinical decision. Stimulation settings,
including contact selection, were based on psychiatrist
assessment of response to test stimulation, and adjusted
when necessary over the entire follow-up period. Anato-
mical location of the active contacts therefore varied
according to both initial implant and programming techni-
que over the course of the study. The most common loca-
tion for the center of the active contact was the anterior
internal capsule (ventral part of AIC, in 31 hemispheres,
56% of the 55 stimulated hemispheres), followed by the bed
nucleus of the stria terminalis (15 hemispheres, 27%), lat-
eral hypothalamus (3 hemispheres, 5%), globus pallidus
externus (2 hemispheres) and dorsal part of AIC (1 hemi-
sphere). As mentioned above, some patients had leads with
more than one active contact, and in three of these patients,
the centers of the active contacts were located in adjacent
brain areas. In one hemisphere, this was in the ventral part
of AIC plus bed nucleus of the stria terminalis, in another
one in the ventral part of AIC plus lateral hypothalamus,
and in a third hemisphere this was in the ventral part of AIC
plus globus pallidus externus plus dorsal part of AIC. Note
that the actual stimulated anatomical structures probably
extended beyond the center of each active contact displayed
in Fig. 1 [8]. Of the three patients with their stimulator
turned off at Month 12, two patients had the device
explanted (in one case due to intracranial infection and in
the other case due to a device event: extension migration/
dislodgement). The third patient had a temporary suspen-
sion of therapy due to possible magnetic ﬁeld action which
may have inadvertently shut off the stimulation.
Stimulation settings were rather high compared to DBS for
movement disorders (mean [SD] at Month 12: amplitude 4.7
(1.8) Volts, pulse duration 221 (63) µs, frequency 130 (3) Hz)
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but were in line with previous literature on DBS for OCD
[8, 26]. A total of eight battery replacements were made for
end of battery life during the study (all of them were made
between 5 and 10 months after the original implant).
Safety evaluation
Adverse events
An overview of AEs that occurred during the study is
presented in Table 1. All patients experienced AEs (195 in
total), with the majority of them being mild (n= 102, cor-
responding to 52% of AEs) or moderate (73, 37%). Out of
the 195 AEs, 123 (63%) were device-related, i.e. could be
attributed to the device, the procedure or the electrical sti-
mulation. Half of the patients reported between one and ﬁve
AEs each, with the remainder reporting six AEs or more (3
patients reported > 10 AEs). Median time to resolution was
22 days for all AEs.
Totaling serious and nonserious AEs, the Medical Dic-
tionary for Regulatory Affairs (MedDRA) High Level
Group Term (HLGT) with the highest incidence of AEs was
J. M. Menchón et al.
Anxiety disorders and symptoms, followed by Neurological
disorders not elsewhere classiﬁed, and Headaches. Accord-
ing to the Clinical Events Committee classiﬁcation, the
etiology with the highest AE incidence was ‘programming/
stimulation’, with events reported in 26 patients (84% of
enrolled), followed by ‘New illness, injury, condition’
(13, 42%), ‘preexisting condition, worsening or exacerba-
tion’ (11, 35%), ‘incisional site/device tract’ (11, 35%),
‘Medication’ (10, 32%) and ‘Unknown’ (10, 32%).
Serious adverse events
A total of 36 SAEs was reported by 16 patients (52%)
(Table 2). The most frequently reported SAE was OCD
worsening (10 events in 9 patients, 29%), followed by
seizures (5 events in 4 patients, 13%), anxiety and hypo-
mania (2 events in 2 patients each, 6%). Some investigators
considered ‘OCD worsening’ as referring to the preceding
visit, others to the baseline visit. Two generalized tonic-
clonic seizures occurred in a patient in whom an electrode
was misplaced in the dorsal caudate nucleus. One patient
presented a similar episode 48 h after electrode implant
accompanied by a confusional state. In one patient a seizure
occurred in the context of an intracranial infection. In one
patient a single seizure episode took place 6 months after
implantation while modifying stimulation parameters. It is
noteworthy that 8 of the 36 SAEs were reported in one
single patient (convulsion, coma, infection, pleural effusion,
axillary vein thrombosis, bronchopneumonia, pneu-
mothorax, and shock), all attributed to surgery-related
infection. This patient’s DBS system was explanted
5.4 months after implantation (the patient remained in the
study, but without DBS) and almost all events resolved
without sequelae; the exceptions were pleural effusion
(resulted in dysphonia) and bronchopneumonia (resulted in
modest dysventilation on the chest X-ray). Overall median
time to resolution was 27 days for SAEs.
None of the AEs led to premature discontinuation of the
study, but AEs led to 12 temporary therapy suspensions in 8
patients for several reasons (seizures, headache, chest pain,
restlessness, hypomania, hypersomnia, and OCD). The vast
majority of AEs was resolved at the end of the study and
only 9 events (5% of total AEs) in 7 patients were ongoing
at the end of the follow-up period (this included two
patients with three SAEs, one with an SAE of hypothyr-
oidism and another patient with SAEs of worsening emo-
tional instability within borderline personality disorder and
suicidal ideation). The six ongoing nonserious AEs were
dizziness, hypercholesterolemia, gastritis, implant site pain
(one subject each), and one subject with both hypothyr-
oidism and tremor.
Acute stimulation-induced effects (ASIEs)
ASIEs were not included in the deﬁnition of an AE, but
provided valuable information on DBS treatment. By deﬁ-
nition, these effects were transient and resolved with or
without programming changes prior to the patient leaving a
study visit. A total of 588 ASIEs were reported at 34% of
visits at which stimulation parameters were adjusted. The
most common ASIEs experienced at the ﬁrst parameter
selection visit were increased anxiety (10 patients, 33% of
stimulated), sensations of cold or hot (9, 30%), other mood
and anxiety effects (8, 27%), and skin (facial) ﬂushing
(7, 23%).
Efﬁcacy
Frequency distributions of Y-BOCS total score at each
visit are shown in Fig. 2. The mean (SD) Y-BOCS total
score for the implanted population decreased from base-
line to the ﬁrst Parameter Selection visit (the Y-BOCS
was assessed at this visit prior to any stimulation) from
34.9 (2.9) to 30.0 (6.1), corresponding to a mean (SD)
reduction from baseline of 14% (15%). Following
Fig. 1 Coronal brain atlas slices showing the location of the center of
all 58 cathodes at 12 months follow-up (26 patients). Contacts are
depicted with different symbols, according to the patient’s Y-BOCS
improvement at 12 months follow-up (versus preoperative baseline):
● indicates less than 25% improvement,▲ 25–35%, ■ 35–65% and
⋆ more than 65% improvement. One subject was excluded because,
although the neurostimulator was on at Month 12, it was unclear for
what actual duration the therapy had been delivered, due to low
impedance. Note that three patients were stimulated with two or three
contacts per hemisphere, whereas one patient was only stimulated with
one active contact on the right side. All 22 other patients were sti-
mulated bilaterally, with one cathode in each hemisphere. In the top
left corner of each slice, the position anterior (−) or posterior (+) to
the anterior commissure is speciﬁed. For each coronal slice, the right
and left hemispheres are depicted adjacently, in accordance with the
radiological convention (right hemisphere shown on the left side and
vice versa). Instead of displaying complete coronal slices, a detailed
window is shown, dorsally bordered by the corpus callosum and
ventrally extending 10 mm below the intercommissural plane, as
indicated in the bottom left panel. In addition, a sagittal view of the
brain with indication of the relevant coronal slices is shown. ac
anterior commissure, Ac nucleus accumbens, AIC anterior limb of the
internal capsule, AM anteromedial thalamic nucleus, BST bed nucleus
of the stria terminalis, cc corpus callosum, Cd caudate nucleus, EGP
external globus pallidus, Fa fasciculosus nucleus, FCd fundus region
of caudate nucleus, FLV frontal horn of lateral ventricle, FPu fundus
region of putamen, fx fornix, IC internal capsule, IGP internal globus
pallidus, ITP inferior thalamic peduncle, LH lateral hypothalamic area,
lml lateral medullary lamina of globus pallidus, LS lateral septal
nucleus; LV lateral ventricle, mfb medial forebrain bundle, mml
medial medullary lamina of globus pallidus, MPO medial preoptic
nucleus, Pa paraventricular hypothalamic nucleus, PRt prereticular
zone, Pu putamen, PV paraventricular thalamic nucleus, Rt reticular
thalamic nucleus, SCGP supracapsular part of globus pallidus, st stria
terminalis, VA ventral anterior thalamic nucleus, 3V third ventricle.
Images are adapted from Mai’s Atlas of the Human Brain [43]
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initiation of stimulation, a further decrease in the mean Y-
BOCS was observed during the treatment period, with an
improvement observed as early as Month 3. The mean
(SD) score was 22.3 (8.2) at Month 3, 19.8 (8.3) at Month
6, and 20.0 (9.5) at Month 12, corresponding to a mean
(SD) reduction from baseline of 36% (23%), 43% (23%),
and 42% (27%), respectively. The majority of patients (17
of 30, 57%) could be classiﬁed as Y-BOCS responders (at
least a 35% reduction in Y-BOCS score from baseline) at
Month 3. The number of responders at Month 6 and
Month 12 was 21 patients (70%) and 18 patients (60%),
respectively. Among responders at Month 12, most
patients had active contacts located bilaterally within AIC
(6 patients, 33%) or BST (6 patients, 33%). Among
nonresponders, most patients had active contacts located
bilaterally within AIC (4 patients, 33%) or patients were
not receiving stimulation (3 patients, 25%). Mean scores
for obsessions and compulsions decreased with a similar
magnitude to 10.0 (5.1) and 10.0 (4.6) at Month 12 for Y-
BOCS obsessions and compulsions, respectively.
Changes in additional efﬁcacy measures supported the
observed effects on Y-BOCS, with mean values for most
measures (GAF, MADRS, CGI, and EQ-5D) showing
improvement, and the YMRS maintaining a low level, over
the 12 months of follow-up (Fig. 3). Note that, analogous to
the Y-BOCS total score, the mean MADRS scores also
decreased in those 9 patients suffering from comorbid major
depressive disorder.
Fig. 2 Frequency distribution of
the individual patients’ Y-BOCS
Total scores at each visit. Total
n= 31 enrolled patients.
Stimulation status: white= on
bilateral, black= off, hatched=
on unilateral. X-axis: Y-BOCS
total score; Y-axis: count of
patients
A prospective international multi-center study on safety and efﬁcacy of deep brain stimulation for. . .
Fig. 3 Efﬁcacy measurements’ changes across visits. n= 30 implanted
patients. The blue circles and solid lines represent all patients. On the
MADRS plot, the green squares and dotted line represent the 9 patients
with baseline MDD. Scr screening visit, BL baseline visit, PS para-
meter selection visit. Error bars represent ± 1 standard error. Y-BOCS
Yale–Brown Obsessive-Compulsive Scale, MADRS Montgomery-
Åsberg Depression Rating Scale, GAF Global Assessment of Func-
tioning, EQ-5D EuroQol group-5 Dimensional, YMRS Young Mania
Rating Scale, CGI-I Clinician Global Impressions of Improvement,
CGI-S Clinician Global Impressions of Severity
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Discussion
This is the ﬁrst prospective, international multi-center study
designed to monitor the safety and efﬁcacy of DBS of the
AIC for patients with chronic, severe, treatment-resistant
OCD. Although AEs were frequent, the majority were mild
or moderate, transient, and mostly related to programming
and could then be resolved by adjusting stimulation para-
meters. Only nine AEs (5% of the total) persisted at the end
of the study, while the majority resolved within an average
of three weeks. After 12 months of stimulation, the mean Y-
BOCS score was decreased by 42%, and 60% of the
patients could be considered responders. Comorbid
depressive symptoms, global functioning and health level
all improved in response to DBS.
A recent review on the safety proﬁle of DBS use in
psychiatric disorders concluded that the majority of reported
complications for these indications are mild to moderate,
stimulation-related, and transitory as many resolved
promptly with modiﬁcation of stimulation parameters [17].
For OCD patients, mood changes, including both depressive
and manic states, as well as anxiety symptoms going from
transient OCD worsening to inner tension or restlessness are
the most frequently reported AEs associated with DBS use
[15, 17]. Ventral stimulation of the AIC-nucleus accumbens
has been described to be associated with the emergence of
fear and panic attacks in OCD patients [27] as well as with
apathy and depression in patients with Gilles de La Tourette
syndrome [28]. Hypomania was frequently observed in
OCD patients treated by STN DBS. [13] Accordingly, in
our study, OCD, seizures, anxiety, and hypomania were
recorded as the most frequent SAEs. Worsening of OCD
symptoms was the most common adverse event recorded
per protocol (and considered ‘serious’ by deﬁnition) in our
study. However, although ﬂuctuations in symptom severity
were common during adjustment of stimulation parameters,
they were always transient and reversible.
Four patients in our study, 13% of the sample, presented
with seizures, mostly generalized tonic-clonic seizure epi-
sodes. Seizures have been described as an uncommon
complication of DBS surgery in patients with movement
disorders, with percentages ranging from 4.3% to 6.4% of
the samples [29, 30] and have been reported previously in
DBS patients with OCD [8, 26]. They generally occur
within 48 h of surgery and are especially associated with the
presence of intracranial vascular events including hemor-
rhage, edema, or ischemia [29].
While seizures are an expected potential side effect of
DBS therapy, this higher than expected number may have
come from a combination of factors in our sample. Unlike
in the other studies on DBS for OCD, one subject experi-
enced an intracranial infection leading to a seizure. Another
subject experienced two generalized tonic-clonic seizures
when receiving high frequency stimulation through a mis-
placed electrode in the caudate nucleus. In a few animal
models and human studies, low frequency stimulation of the
caudate nucleus (<50 Hz) could reduce epileptic activity,
while high frequency stimulation of the caudate nucleus (i.e.
in ranges similar to those used in our study) could increase
epileptic activity [31]. A similar mechanism may have
caused these two seizures. The remaining two subjects with
seizures are within the range that was reported in prior DBS
for OCD studies [8, 26].
Suicide risk associated with DBS use in OCD was low in
our study, with one patient reporting suicidal ideation and
one performing a suicide attempt. Suicidality has been
described as the most frequent SAE of DBS in psychiatric
disorders, especially in patients with Major Depressive
Disorder (MDD) [17]. According to a recent meta-analysis,
3.4% of OCD patients who received DBS reported suicidal
ideation [15]. Suicidality is a complex multi-factorial phe-
nomenon and published studies have not been able to
establish a deﬁnitive causal relationship between DBS
surgery and suicidal ideation or attempts [32, 33]. Post-
operative depression, being single, and a previous history of
impulse control-related behaviors emerged as independent
risk factors in case series of parkinsonian patients [34, 35].
The presence of unrealistic expectations about surgical
outcome has also been suggested to play a signiﬁcant role in
suicidal ideation.
Surgery- and device-related complications were limited,
with implant site pain and irritation as the most frequent
ones. Nevertheless, one patient had an intracranial infection
that forced an explant of the DBS system and led to per-
manent sequelae in the form of dysphonia and modest
pulmonary dysventilation. ICH, one of the most severe risks
of DBS, did not occur in our sample. ICH in OCD patients
implanted for DBS has been reported to arise in 2.2–2.6%
of the cases [7, 8, 15], a percentage somewhat similar to the
rate of ICH in DBS for movement disorders, estimated to be
between 0.8 and 3.3% [36, 37].
Sixty percent of the patients qualiﬁed as treatment
responders. The mean reduction on Y-BOCS scores was
over 40%. These results are almost identical to those
reported in a meta-analysis of DBS use in OCD patients
[15] and conﬁrm what can be expected from the techni-
que concerning efﬁcacy. Interestingly, a decrease of 14%
on Y-BOCS scores was detected immediately after the
device implant and before initiating stimulation, an effect
that may be attributed to placebo response, regression to
the mean, or to the edema inﬂicted by the device
implantation and that was largely known to occur in
lesional procedures [38]. Response to DBS in OCD
patients seems to occur relatively early, with a clear and
signiﬁcant amelioration of symptom severity after just
three months of active stimulation.
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Regrettably, 40% of the patients in our sample did not
reach the responder criterion at the Month 12 visit, although
5 of these 12 ‘nonresponders’ did reach partial response
(25–35% reduction vs. baseline Y-BOCS score). In the case
of OCD, the therapeutic effect of DBS has been tentatively
related to its capacity to modulate abnormal activity and
synaptic connectivity in circuits involving the orbitofrontal
cortex (OFC), anterior cingulate cortex (ACC) and striatum
[16, 39], circuits that have been implicated in the patho-
physiology of the disorder [40]. Individual anatomical
variability of the orbitofrontothalamic ﬁbers in the stimu-
lated region might partially explain differences in the
response rate. In addition, variations in the ﬁnal locations of
the active electrode contacts could also be related to
response rates. Recently developed tractographic techniques
allow measuring this individual variability, and thus might
permit targeting individualized anatomical structures for
maximum response to DBS [41].
Limitations of the study: This is a nonrandomized study,
based on nonblinded assessments, and therefore inﬂuence of
placebo effect on efﬁcacy could not be ruled out. However,
randomized studies in OCD patients comparing active
versus sham DBS have consistently reported severe clinical
deterioration associated with sham conditions, suggesting
that a placebo effect, quite limited in OCD patients in
general, is almost absent in this group of extremely disabled
patients [8–14]. A group of severe treatment-resistant OCD
patients not submitted to DBS and treated with conventional
therapy was not included in our study and would have
constituted a good comparison group to ascertain changes
over time in this kind of patients. However, a spontaneous
remission or improvement of symptoms in this group of
patients is extremely unlikely. The follow-up period in our
study lasted just 12 months, so evidence of delayed adverse
effects related to chronic brain stimulation as well as long-
term sustainability of clinical response could not be asses-
sed beyond this period. Conversely, patients may poten-
tially reach responder status later than 12 months of follow-
up. In addition, prior research with follow-up periods of
several years does seem to indicate a sustained therapeutic
response [42]. Finally, it cannot be ruled out that the par-
ticipation of several centers may have inﬂuenced the var-
iation found in some aspects of the therapy, such as
electrode location (i.e. 56% of the active contacts were
located in the AIC). This variation appeared even though all
sites were trained on lead implant technique and were
offered technical support (Supplementary Material). In this
regard and considering the size of the electrode contacts, it
must be said that the location of the geometric center of the
active contact is only a reduced representation of the brain
structures that are being stimulated. At the stimulation set-
tings used in this study, contacts with a geometric center
located in neighboring brain areas, e.g. the bed nucleus of
the stria terminalis, may also reach the AIC, implying that
more than 56% of hemispheres received stimulation in the
AIC. In our opinion, our results reﬂect the current ‘real-
world’ situation of DBS treatment in OCD, which is here
prospectively assessed in an international multicentric way
for the ﬁrst time.
In conclusion, DBS for severe treatment-resistant OCD
patients reduced the severity of obsessive-compulsive
symptoms by an average of 40%, with a responder rate of
60%. Severe and permanent adverse effects happened,
mainly related to infection and seizures. However, most
AEs were mild or moderate, transient and related to sti-
mulation and tended to resolve by adjustment of stimula-
tion, as seen in DBS for movement disorders. In this severe
treatment-resistant population, this open-label study sup-
ports that the potential beneﬁts outweigh the potential risks
of DBS.
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